Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	884.61M
Revenue (ttm)	170.24M
Net Income (ttm)	56.03M
Shares Out	15.94M
EPS (ttm)	3.43
PE Ratio	16.20
Forward PE	27.04
Dividend	1.93 (3.45%)
Ex-Dividend Date	Jun 4, 2025

Volume	11,600
Average Volume	25,068
Open	56.30
Previous Close	55.90
Day's Range	55.50 - 56.80
52-Week Range	41.60 - 80.60
Beta	1.29
RSI	38.14
Earnings Date	Jul 23, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR